The DOI matches its Crossref record; 280 of the 280 references it cites were found in a registry or an index.
Immunologic tumor microenvironment modulators for turning cold tumors hot
Open accessAbstract
Tumors can be classified into distinct immunophenotypes based on the presence and arrangement of cytotoxic immune cells within the tumor microenvironment (TME). Hot tumors, characterized by heightened immune activity and responsiveness to immune checkpoint inhibitors (ICIs), stand in stark contrast to cold tumors, which lack immune infiltration and remain resistant to therapy. To overcome immune evasion mechanisms employed by tumor cells, novel immunologic modulators have emerged, particularly ICIs targeting cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) and programmed cell death protein 1/programmed death‐ligand 1(PD‐1/PD‐L1). These agents disrupt inhibitory signals and reactivate the immune system, transforming cold tumors into hot ones and promoting effective antitumor responses. However, challenges persist, including primary resistance to immunotherapy, autoimmune side effects, and tumor response heterogeneity. Addressing these challenges requires innovative strategies, deeper mechanistic insights, and a combination of immune interventions to enhance the effectiveness of immunotherapies. In the landscape of cancer medicine, where immune cold tumors represent a formidable hurdle, understanding the TME and harnessing its potential to reprogram the immune response is paramount. This review sheds light on current advancements and future directions in the quest for more effective and safer cancer treatment strategies, offering hope for patients with immune‐resistant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–280 of 280
Abebe, E. C., Shiferaw, M. Y., Admasu, F. T., & Dejenie, T. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991092 · Cited by 124
Emerging Concepts Linking Obesity with the Hallmarks of Cancer
Donohoe, C. L., Lysaght, J., O'Sullivan, J. N., & Reynolds, J. V. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.08.004 · Cited by 123
Wang, M. M., Coupland, S. E., Aittokallio, T. A., & Figueiredo, C. R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02361-4 · Cited by 118
Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?
Garg, A. D., Dudek, A. M., & Agostinis, P. (2013) · BioFactors · doi:10.1002/biof.1125 · Cited by 117
Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
Sutherland, S., Ju, X., Horvath, L. G., & Clark, G. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641307 · Cited by 117
Hasmim, M., Noman, M. Z., Messai, Y., Bordereaux, D., Gros, G., Baud, V., & Chouaïb, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1302140 · Cited by 115
Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity
Terry, S., Buart, S., & Chouaïb, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01625 · Cited by 113
Saung, M. T., Pelosof, L. C., Casak, S. J., Donoghue, M. B., Lemery, S. J., Yuan, M., Rodríguez, L., Schotland, P., Chuk, M. K., Davis, G., et al. (2021) · The Oncologist · doi:10.1002/onco.13819 · Cited by 112
Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
Frederico, S. C., Hancock, J. C., Brettschneider, E. E. S., Ratnam, N. M., Gilbert, M. R., & Terabe, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672508 · Cited by 108
Hematopoietic stem cell origin of adipocytes
Sera, Y., LaRue, A. C., Moussa, O., Mehrotra, M., Duncan, J. D., WILLIAMS, C. R., Nishimoto, E., Schulte, B. A., Watson, P. M., Watson, D. K., et al. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.06.008 · Cited by 106
Shah, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Pierce, W. F., Nair, A., Herz, J., Robertson, K. J., Mixter, B. D., Tang, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1110 · Cited by 105
Advances in personalized cancer immunotherapy
Kakimi, K., Karasaki, T., Matsushita, H., & Sugie, T. (2016) · Breast Cancer · doi:10.1007/s12282-016-0688-1 · Cited by 105
Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy
Han, J., Lim, J., Wang, C. J., Han, J., Shin, H. E., Kim, S.-N., Jeong, D., Lee, S. H., Chun, B.-H., Park, C. G., et al. (2023) · Nano Convergence · doi:10.1186/s40580-023-00385-3 · Cited by 103
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., Yohannan, T. K., & Mittra, E. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002453 · Cited by 101
Kratky, W., Sousa, C. R. E., Oxenius, A., & Spörri, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108945108 · Cited by 101
Atezolizumab for the treatment of breast cancer
Reddy, S. M., Carroll, E., & Nanda, R. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1732211 · Cited by 94
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
Khan, Z., Di Nucci, F., Kwan, A., Hammer, C., Mariathasan, S., Rouilly, V., Carroll, J., Fontes, M., Ley Acosta, S., Guardino, E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922867117 · Cited by 91
Cella, D. F., Motzer, R. J., Suárez, C., Blum, S. I., Ejzykowicz, F., Hamilton, M., Wallace, J. F., Şimşek, B., Zhang, J. H., Ivanescu, C., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00693-8 · Cited by 88
Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
Kudo, M. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-143 · Cited by 88
Tumor‐associated macrophage‐targeted therapeutics in ovarian cancer
An, Y., & Yang, Q. (2020) · International Journal of Cancer · doi:10.1002/ijc.33408 · Cited by 86
Akinboro, O., Larkins, E., Pai-Scherf, L. H., Mathieu, L. N., Ren, Y., Cheng, J., Fiero, M. H., Fu, W., Bi, Y., Kalavar, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3844 · Cited by 85
Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma.
Mansh, M. D. (2011) · PubMed Central · Cited by 82
Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics
Patel, H., Nilendu, P., Jahagirdar, D., Pal, J. K., & Sharma, N. K. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1394538 · Cited by 81
Characterization of Transplanted Green Fluorescent Protein+ Bone Marrow Cells into Adipose Tissue
Tomiyama, K., Murase, N., Stolz, D. B., Toyokawa, H., O’Donnell, D. R., Smith, D. M., Dudas, J. R., Rubin, J. P., & Marra, K. G. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0567 · Cited by 78
Dwyer, A. R., Greenland, E. L., & Pixley, F. J. (2017) · Cancers · doi:10.3390/cancers9060068 · Cited by 77
Nivolumab for the treatment of colorectal cancer
Smith, K. M., & Desai, J. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1480942 · Cited by 76
Nam, S., Lee, A., Lim, J., & Lim, J.-S. (2019) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.201 · Cited by 68
Nakajima, E. C., Vellanki, P. J., Larkins, E., Chatterjee, S., Mishra-Kalyani, P. S., Bi, Y., Qosa, H., Liu, J., Zhao, H., Biable, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1466 · Cited by 68
Cancer neoantigens as potential targets for immunotherapy
Ma, W., Pham, B., & Li, T. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10091-1 · Cited by 66
Shimabukuro‐Vornhagen, A., Draube, A., Liebig, T. M., Rothe, A., Kochanek, M., & von Bergwelt‐Baildon, M. S. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-47 · Cited by 65
Hu, H., Zakharov, P. N., Peterson, O. J., & Unanue, E. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019743117 · Cited by 64
Human Papillomavirus-Associated Cancers
Alhamlan, F. S., Al‐Fageeh, M. B., Mushait, M. A. A., Al-Badawi, I. A., & Al‐Ahdal, M. N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-67452-6_1 · Cited by 64
Cancer immunotherapy: how low-level ionizing radiation can play a key role
Janiak, M. K., Wincenciak, M., Cheda, A., Nowosielska, E. M., & Calabrese, E. J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1993-z · Cited by 63
Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
Lim, C. J., Nguyen, P. H. D., Wasser, M., Kumar, P., Lee, Y. H., Nasir, N. J. M., Chua, C. J. H., Lai, L., Hazirah, S. N., Loh, J. J. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615091 · Cited by 63
Immunological classification of tumor types and advances in precision combination immunotherapy
Ren, X., Guo, S., Guan, X., Kang, Y., Liu, J., & Yang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.790113 · Cited by 62
Emerging CAR T Cell Strategies for the Treatment of AML
Vishwasrao, P., Li, G., Boucher, J. C., Smith, D. L., & Hui, S. K. (2022) · Cancers · doi:10.3390/cancers14051241 · Cited by 62
Vellanki, P. J., Mulkey, F. A., Jaigirdar, A. A., Rodríguez, L., Wang, Y., Xu, Y., Zhao, H., Liu, J., Howe, G. A., Wang, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4338 · Cited by 60
Jain, K. K. (2020) · Medical Principles and Practice · doi:10.1159/000511107 · Cited by 54
Luangwattananun, P., Junking, M., Sujjitjoon, J., Wutti‐in, Y., Poungvarin, N., Thuwajit, C., & Yenchitsomanus, P. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-06032-3 · Cited by 53
Immunometabolism in the Tumor Microenvironment
Roy, D. G., Kaymak, I., Williams, K. S., Ma, E. H., & Jones, R. G. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055817 · Cited by 50
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma
Gaiser, M. R., Bongiorno, M. A., & Brownell, I. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445966 · Cited by 49
Cheadle, E. J., Rothwell, D. G., Bridgeman, J. S., Sheard, V., Hawkins, R. E., & Gilham, D. E. (2011) · Gene Therapy · doi:10.1038/gt.2011.192 · Cited by 48
Ascierto, P. A., Lewis, K. D., Giacomo, A. M. D., Демидов, Л. В., Mandalà, M., Bondarenko, I., Herbert, C., Mackiewicz, A. A., Rutkowski, P. L., Guminski, A. D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.002 · Cited by 48
Giustarini, G., Pavesi, A., & Adriani, G. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.689245 · Cited by 45
Update on use of aldesleukin for treatment of high-risk metastatic melanoma
Wargo, J. A., Reuben, A., Cooper, Z. A., & Amaria, R. N. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s61590 · Cited by 43
Mau‐Sørensen, M., Ros, W., Rodriguez-Ruiz, M. E., Robbrecht, D. G. J., Rohrberg, K. S., Martín-Liberal, J., Lassen, U., Melero, I., Lolkema, M. P., Tabernero, J. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15155 · Cited by 42
Adult immuno-oncology: using past failures to inform the future
Rahman, M., Sawyer, W. G., Lindhorst, S., Deleyrolle, L. P., Harrison, J. K., Karachi, A., Dastmalchi, F., Flores‐Toro, J., Mitchell, D. A., Lim, M. K., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa116 · Cited by 42
Mostafavi, S., Zalpoor, H., & Hassan, Z. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00356-2 · Cited by 42
Self-citationChen, C., Li, A., Sun, P., Xu, J., Du, W., Zhang, J., Liu, Y., Zhang, R., Zhang, S., Yang, Z., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.039 · Cited by 41
Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39 · cited 1×
“The constrained clinical advantages observed in a relatively minor proportion of patients can be attributed to various factors, chief among them being the dearth or restricted infiltration of immune cells within the microenvironment [183].”
BackgroundMigden, M. R., Chandra, S., Rabinowits, G., Chen, C.-I., Desai, J., Seluzhytsky, A., Sasané, M., Campanelli, B., Chen, Z., Freeman, M. L., et al. (2020) · Future Oncology · doi:10.2217/fon-2019-0762 · Cited by 39
Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow
Xiong, F., Wang, Q., Wu, G., Liu, W., Wang, B., & Chen, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00415-y · Cited by 37
Inducing immunogenic cell death in immuno-oncological therapies
Ti, D., Yan, X., Wei, J., Wu, Z., Wang, Y., & Han, W. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.01.01 · Cited by 34
Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
Siemińska, I., & Baran, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.862416 · Cited by 34
Strategies for Heating Up Cold Tumors to Boost Immunotherapies
Zabransky, D. J., Yarchoan, M. M., & Jaffee, E. M. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-040258 · Cited by 34
Durvalumab for the treatment of non-small cell lung cancer
Murakami, S. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1699407 · Cited by 33
Igniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition
Chen, W., Ma, Y., Wang, F., Liao, Y., Chen, Y., Zhao, B., Zhao, Q., Wang, D., & Tang, D. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221120708 · Cited by 32
Neoantigens and their potential applications in tumor immunotherapy (Review)
Fang, X., Guo, Z., Liang, J., Wen, J., Liu, Y., Guan, X., & Hong, L. (2022) · Oncology Letters · doi:10.3892/ol.2022.13208 · Cited by 31
Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer
Noguchi, E., Shien, T., & Iwata, H. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa230 · Cited by 30
Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer
Shackleton, E. G., Ali, H. Y., Khan, M. A., Pockley, A. G., & McArdle, S. (2021) · Cancers · doi:10.3390/cancers13051145 · Cited by 30
Challenges and exploration for immunotherapies targeting cold colorectal cancer
Li, D., Tang, Y., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i1.55 · Cited by 28
Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy
Pol, J. G., & Kroemer, G. (2018) · Cell Research · doi:10.1038/s41422-018-0031-9 · Cited by 27
Wang, S., Wang, Z., Li, Z., Xu, J., Meng, X., Zhao, Z., & Hou, Y. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201240 · Cited by 26
Sinner, F., Pinter, M., Scheiner, B., Ettrich, T. J., Sturm, N., Gonzalez-Carmona, M. A., Waidmann, O., Finkelmeier, F., Himmelsbach, V., Toni, E. N. D., et al. (2022) · Cancers · doi:10.3390/cancers14235966 · Cited by 25
Pieper, A. A., Zangl, L. M., Speigelman, D. V., Feils, A. S., Hoefges, A., Jagodinsky, J. C., Felder, M. A. R., Tsarovsky, N. W., Arthur, I. S., Brown, R. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.763888 · Cited by 23
Anderson, M. K., Torosyan, A., & Halford, Z. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211026338 · Cited by 22
Cheng, S., Pei, R., Li, J., Li, B., Tang, L., Yin, T., & Liu, S. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4294 · Cited by 21
Dostarlimab for recurrent mismatch repair‐deficient endometrial cancer: A cost‐effectiveness study
Dioun, S. M., Chen, L., Melamed, A., Gockley, A. A., Clair, C. M. S., Hou, J. Y., Khoury‐Collado, F., Hur, C., Elkin, E. B., Accordino, M. K., et al. (2022) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17338 · Cited by 20
Nivolumab for the treatment of bladder cancer
Hakenberg, O. W. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1353076 · Cited by 16
Cemiplimab for locally advanced and metastatic basal cell carcinoma
Damsin, T., Lebas, E., Marchal, N., Rorive, A., & Nikkels, A. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2043748 · Cited by 16
Larkin, J., Oya, M., Martignoni, M., Thistlethwaite, F. C., Nathan, P., Ornstein, M. C., Powles, T. B., Beckermann, K. E., Balar, A. V., McDermott, D. F., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac243 · Cited by 16
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
Oriol, A., Abril, L., Torrent, A., Ibarra, G., & Ribera, J. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211019622 · Cited by 14
Bou-Dargham, M. J., Sha, L., Sarker, D. B., Krakora-Compagno, M. Z., Chen, Z., Zhang, J., & Sang, Q. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119355 · Cited by 14
Lisocabtagene Maraleucel for the treatment of B-cell lymphoma
Iragavarapu, C., & Hildebrandt, G. C. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1933939 · Cited by 13
Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma
Bergsma, E. J., Elgawly, M., Mancuso, D., Orr, R., Vuskovich, T., & Seligson, N. D. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231187421 · Cited by 13
Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities
Rezaei, M., Danilova, N. D., Soltani, M., Savvateeva, L. V., Tarasov, V. V., Ganjalıkhani-Hakemi, M., Bazhin, A. V., & Zamyatnin, A. A. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220214103533 · Cited by 11
Jain, K. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-62080-6_20 · Cited by 11
Pembrolizumab use in bladder cancer: a tale of two trials
Aragon‐Ching, J. B. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00499-5 · Cited by 10
Park, M., Kuen, D., Park, J., Choi, M., Kim, Y., Roh, E. C., Choi, Y. J., Kim, Y. G., Chung, Y., Cho, S. Y., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006084 · Cited by 8
Imiquimod for Superficial Basal Cell Carcinomas
Mahatma, G., Sweeney, A. R., & Yen, M. T. (2020) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000299 · Cited by 4
Metadata
- Authors
- Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N.
- Venue
- Cancer Communications
- Published
- 2024-03-29
- Volume
- 44
- Issue
- 5
- Pages
- 521-553
- ISSN
- 1000-467X (ISSN-L)
- 2523-3548
- OpenAlex
- W4393308058
- Cited by
- 364
- References
- 280
- FWCI
- 55.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.